65.35
전일 마감가:
$64.77
열려 있는:
$64.77
하루 거래량:
1.69M
Relative Volume:
2.30
시가총액:
$3.65B
수익:
$76.81M
순이익/손실:
$-162.42M
주가수익비율:
-21.86
EPS:
-2.99
순현금흐름:
$-122.49M
1주 성능:
+3.73%
1개월 성능:
+5.49%
6개월 성능:
-17.36%
1년 성능:
+20.75%
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
ACLX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ACLX
Arcellx Inc
|
65.35 | 3.65B | 76.81M | -162.42M | -122.49M | -2.99 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-08 | 개시 | Redburn Atlantic | Buy |
2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
2024-05-31 | 개시 | Piper Sandler | Overweight |
2024-03-07 | 개시 | Morgan Stanley | Overweight |
2024-01-04 | 재확인 | Needham | Buy |
2023-12-19 | 개시 | Scotiabank | Sector Outperform |
2023-10-30 | 개시 | TD Cowen | Outperform |
2023-10-17 | 개시 | UBS | Buy |
2023-05-18 | 개시 | Truist | Buy |
2023-04-14 | 개시 | Robert W. Baird | Outperform |
2023-03-14 | 개시 | Stifel | Buy |
2023-02-13 | 개시 | H.C. Wainwright | Buy |
2022-12-13 | 재개 | BofA Securities | Buy |
2022-10-31 | 개시 | Guggenheim | Buy |
2022-10-27 | 개시 | Needham | Buy |
2022-07-20 | 개시 | Canaccord Genuity | Buy |
2022-03-01 | 개시 | BofA Securities | Buy |
2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Citi initiates Arcellx stock with buy rating on cell therapy potential - Investing.com
Citi initiates Arcellx stock with buy rating on cell therapy potential By Investing.com - Investing.com South Africa
Cancer Cell Market Exclusive Report with Detailed Study Analysis | Abbott Laboratories, Cellectis, Arcellx, GE - newstrail.com
Citigroup Initiates Arcellx at Buy With $110 Price Target - MarketScreener
Arcellx initiated with a Buy at Citi - TipRanks
Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus
Aileen Fernandes | People on The MoveSan Francisco Business Times - The Business Journals
Aileen Fernandes - The Business Journals
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment - TipRanks
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential - TipRanks
ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus
Arcellx stock maintains buy rating at H.C. Wainwright on launch plans - Investing.com
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating - TipRanks
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning - TipRanks
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy - TipRanks
Rhumbline Advisers Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Transcript : Arcellx, Inc.Special Call - MarketScreener
(ACLX) Technical Data - news.stocktradersdaily.com
Arcellx’s SWOT analysis: CAR-T pioneer’s stock poised for myeloma market shake-up - Investing.com
arcellx director Kavita Patel sells shares worth $101,040 By Investing.com - Investing.com Nigeria
arcellx director Kavita Patel sells shares worth $101,040 - Investing.com
Brokers Set Expectations for Arcellx FY2026 Earnings - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Two Sigma Investments LP - Defense World
FY2026 EPS Estimates for Arcellx Lifted by Leerink Partnrs - Defense World
Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World
Kalkine: Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media
Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Holds Annual Stockholders Meeting - TipRanks
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister
Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga
Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey
BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arcellx Inc 주식 (ACLX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Patel Kavita | Director |
Jun 10 '25 |
Sale |
67.36 |
1,500 |
101,040 |
0 |
자본화:
|
볼륨(24시간):